Search results
Results from the WOW.Com Content Network
Physiologically based pharmacokinetic (PBPK) modeling is a mathematical modeling technique for predicting the absorption, distribution, metabolism and excretion (ADME) of synthetic or natural chemical substances in humans and other animal species.
Pharmacokinetics is based on mathematical modeling that places great emphasis on the relationship between drug plasma concentration and the time elapsed since the drug's administration. Pharmacokinetics is the study of how an organism affects the drug, whereas pharmacodynamics (PD) is the study of
Pharmacometrics is a field of study of the methodology and application of models for disease and pharmacological measurement.It uses mathematical models of biology, pharmacology, disease, and physiology to describe and quantify interactions between xenobiotics and patients (human and non-human), including beneficial effects and adverse effects. [1]
Biosimulation is becoming increasingly important for drug development. [1] Since on average only 11% of all drug candidates are approved, [2] it is anticipated that biosimulation may be the tool to predict whether a candidate drug will fail in the development process e.g. in clinical trials due to adverse side effects, bad pharmacokinetics or even toxicity.
Explore the concept of PK/PD models, which integrate pharmacokinetics and pharmacodynamics to optimize drug dosing and efficacy.
Leon Aarons is an Australian chemist who researches and teaches in the areas of pharmacodynamics and pharmacokinetics. [1] He lives in the United Kingdom and from 1976 has been a professor of pharmacometrics at the University of Manchester. [2]
IVIVE in pharmacology can be used to assess pharmacokinetics (PK) or pharmacodynamics (PD).. [citation needed]Since biological perturbation depends on concentration of the toxicant as well as exposure duration of a candidate drug (parent molecule or metabolites) at that target site, in vivo tissue and organ effects can either be completely different or similar to those observed in vitro.
The use of trapezoidal rule in AUC calculation was known in literature by no later than 1975, in J.G. Wagner's Fundamentals of Clinical Pharmacokinetics. A 1977 article compares the "classical" trapezoidal method to a number of methods that take into account the typical shape of the concentration plot, caused by first-order kinetics. [8]